The expression of ocular biomarkers provides valuable information for predicting and investigating the efficacy of new ocular therapies during preclinical and clinical research
PRECLINICIAL RESEARCH SERVICE: Follow predictive biomarkers in animal modelsOur multidisciplinary team of scientists works with our customers to identify and quantify predictive ocular biomarkers – such as those involved in neovascularization and the inflammation - in many animal models.
CLINICAL RESEARCH SERVICE: Incorporate ocular biomarkers into the clinical trials design
Dry eye syndrome is a multifactorial disease on the ocular surface, leading to conjunctival inflammation associated with expression of biomarkers such as HLA-DR (Human Leukocyte Antigen).
HLA-DR quantification is very interesting in clinical trials related to ocular surface diseases and is used in the US and EU as an ancillary parameter to be considered.
HLA-DR quantification by flow cytometry has been developed and mastered by our expert since 1997.
ADVANCED TECHNOLOGYIris Pharma has a laboratory equiped with cutting-edge technologies for cellular and molecular biology assays (flow cytometry, RT-qPCR, ELISA and Multiplex).
